Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. / Schmidt, Julie Berg; Gregersen, Nikolaj Ture; Pedersen, Sue D; Arentoft, Johanne L; Ritz, Christian; Schwartz, Thue W.; Holst, Jens Juul; Astrup, Arne; Sjödin, Anders Mikael.

I: American Journal of Physiology: Endocrinology and Metabolism, Bind 306, Nr. 11, 2014, s. E1248-E1256.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Schmidt, JB, Gregersen, NT, Pedersen, SD, Arentoft, JL, Ritz, C, Schwartz, TW, Holst, JJ, Astrup, A & Sjödin, AM 2014, 'Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men', American Journal of Physiology: Endocrinology and Metabolism, bind 306, nr. 11, s. E1248-E1256. https://doi.org/10.1152/ajpendo.00569.2013

APA

Schmidt, J. B., Gregersen, N. T., Pedersen, S. D., Arentoft, J. L., Ritz, C., Schwartz, T. W., ... Sjödin, A. M. (2014). Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. American Journal of Physiology: Endocrinology and Metabolism, 306(11), E1248-E1256. https://doi.org/10.1152/ajpendo.00569.2013

Vancouver

Schmidt JB, Gregersen NT, Pedersen SD, Arentoft JL, Ritz C, Schwartz TW o.a. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. American Journal of Physiology: Endocrinology and Metabolism. 2014;306(11):E1248-E1256. https://doi.org/10.1152/ajpendo.00569.2013

Author

Schmidt, Julie Berg ; Gregersen, Nikolaj Ture ; Pedersen, Sue D ; Arentoft, Johanne L ; Ritz, Christian ; Schwartz, Thue W. ; Holst, Jens Juul ; Astrup, Arne ; Sjödin, Anders Mikael. / Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men. I: American Journal of Physiology: Endocrinology and Metabolism. 2014 ; Bind 306, Nr. 11. s. E1248-E1256.

Bibtex

@article{bead609efd35449da819f5c6ad2e42e3,
title = "Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men",
abstract = "Aim: To examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin and vital signs in healthy overweight men. Methods: 25 healthy, male subjects participated in this randomized, double-blinded, placebo-controlled 4-arm crossover study (BMI:29±3 kg/m2, age:33±9 years). On separate days they received a 150 min intravenous infusion of either a) 0.8pmol/kg/min PYY3-36, b) 1.0 pmol/kg/min GLP-1, c) a+b, or d) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs and blood variables were collected throughout the infusion period. Results: No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2±4.8{\%}, P=0.8) or GLP-1 (-3.0±4.5{\%}, P=0.9). However, the co-infusion reduced energy intake compared to placebo (-30.4±6.5{\%}, P<0.0001) and more than the sum of the monoinfusions (P<0.001), demonstrating a synergistic effect. Co-infusion slightly increased sensation of nausea (P<0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared to placebo (all P<0.05); however, infusions of GLP-1+PYY3-36 resulted in an additional decrease compared to the monoinfusions (both P<0.01).Conclusion: Co-infusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared to placebo. Co-infusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of thesefactors could explain the reduction in energy intake.",
author = "Schmidt, {Julie Berg} and Gregersen, {Nikolaj Ture} and Pedersen, {Sue D} and Arentoft, {Johanne L} and Christian Ritz and Schwartz, {Thue W.} and Holst, {Jens Juul} and Arne Astrup and Sj{\"o}din, {Anders Mikael}",
note = "CURIS 2014 NEXS 112",
year = "2014",
doi = "10.1152/ajpendo.00569.2013",
language = "English",
volume = "306",
pages = "E1248--E1256",
journal = "American Journal of Physiology: Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "11",

}

RIS

TY - JOUR

T1 - Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure and appetite in overweight men

AU - Schmidt, Julie Berg

AU - Gregersen, Nikolaj Ture

AU - Pedersen, Sue D

AU - Arentoft, Johanne L

AU - Ritz, Christian

AU - Schwartz, Thue W.

AU - Holst, Jens Juul

AU - Astrup, Arne

AU - Sjödin, Anders Mikael

N1 - CURIS 2014 NEXS 112

PY - 2014

Y1 - 2014

N2 - Aim: To examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin and vital signs in healthy overweight men. Methods: 25 healthy, male subjects participated in this randomized, double-blinded, placebo-controlled 4-arm crossover study (BMI:29±3 kg/m2, age:33±9 years). On separate days they received a 150 min intravenous infusion of either a) 0.8pmol/kg/min PYY3-36, b) 1.0 pmol/kg/min GLP-1, c) a+b, or d) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs and blood variables were collected throughout the infusion period. Results: No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2±4.8%, P=0.8) or GLP-1 (-3.0±4.5%, P=0.9). However, the co-infusion reduced energy intake compared to placebo (-30.4±6.5%, P<0.0001) and more than the sum of the monoinfusions (P<0.001), demonstrating a synergistic effect. Co-infusion slightly increased sensation of nausea (P<0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared to placebo (all P<0.05); however, infusions of GLP-1+PYY3-36 resulted in an additional decrease compared to the monoinfusions (both P<0.01).Conclusion: Co-infusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared to placebo. Co-infusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of thesefactors could explain the reduction in energy intake.

AB - Aim: To examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin and vital signs in healthy overweight men. Methods: 25 healthy, male subjects participated in this randomized, double-blinded, placebo-controlled 4-arm crossover study (BMI:29±3 kg/m2, age:33±9 years). On separate days they received a 150 min intravenous infusion of either a) 0.8pmol/kg/min PYY3-36, b) 1.0 pmol/kg/min GLP-1, c) a+b, or d) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs and blood variables were collected throughout the infusion period. Results: No effect on energy intake was found after monoinfusions of PYY3-36 (-4.2±4.8%, P=0.8) or GLP-1 (-3.0±4.5%, P=0.9). However, the co-infusion reduced energy intake compared to placebo (-30.4±6.5%, P<0.0001) and more than the sum of the monoinfusions (P<0.001), demonstrating a synergistic effect. Co-infusion slightly increased sensation of nausea (P<0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared to placebo (all P<0.05); however, infusions of GLP-1+PYY3-36 resulted in an additional decrease compared to the monoinfusions (both P<0.01).Conclusion: Co-infusion of GLP-1 and PYY3-36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3-36 in combination compared to placebo. Co-infusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of thesefactors could explain the reduction in energy intake.

U2 - 10.1152/ajpendo.00569.2013

DO - 10.1152/ajpendo.00569.2013

M3 - Journal article

VL - 306

SP - E1248-E1256

JO - American Journal of Physiology: Endocrinology and Metabolism

JF - American Journal of Physiology: Endocrinology and Metabolism

SN - 0193-1849

IS - 11

ER -

ID: 107926442